Erchonia® THL™ for Tinnitus

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Valley Audiology, Concord, CA
Tinnitus
Erchonia® THL™ - Device
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

The purpose of this clinical study is to determine the effectiveness of the Erchonia® THL™, manufactured by Erchonia Corporation (the Company), for prescription home use in providing relief of tinnitus symptoms when used by individuals in their own homes.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: Basline and 4 weeks

Basline and 4 weeks
Tinnitus Functional Index (TFI)

Trial Safety

Trial Design

2 Treatment Groups

Erchonia® THL™
1 of 2
Placebo Laser
1 of 2
Active Control
Non-Treatment Group

64 Total Participants · 2 Treatment Groups

Primary Treatment: Erchonia® THL™ · Has Placebo Group · N/A

Placebo Laser
Device
PlaceboComparator Group · 1 Intervention: Placebo Laser · Intervention Types: Device
Erchonia® THL™
Device
ActiveComparator Group · 1 Intervention: Erchonia® THL™ · Intervention Types: Device

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: basline and 4 weeks
Closest Location: Valley Audiology · Concord, CA
Photo of california 1Photo of california 2Photo of california 3
N/AFirst Recorded Clinical Trial
1 TrialsResearching Tinnitus
0 CompletedClinical Trials

Who is running the clinical trial?

Erchonia CorporationLead Sponsor
37 Previous Clinical Trials
1,816 Total Patients Enrolled
2 Trials studying Tinnitus
26 Patients Enrolled for Tinnitus

Eligibility Criteria

Age 18+ · All Participants · 2 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have a Tinnitus Functional Index (TFI) score of 32 to 72 (Moderate to Big Problem) and you have a hearing loss of less than 60 dB (Moderate or less).

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.